Cancer
Breast cancer
乳腺癌
Tumours or cancer of the breast.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 219
- cities
- 68
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 24% of the world's English-language research papers on breast cancer, 2021–2025 (16% in 2016–2020), and 14% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
219 hospitals in 68 cities
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 18 papers or 1 trial on breast cancer, or was a site in 11 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens breast cancer in that city. 58 more cities are in the menu below.
- 390 papers led
- 333 papers led
- 313 papers led
- 250 papers led
- 246 papers led
- 222 papers led
- 168 papers led
- 135 papers led
- 133 papers ledNo open trial led
- 132 papers led
- 130 papers led
- 116 papers ledNo open trial led
- 116 papers led
- 116 papers led
- 115 papers led
- 114 papers ledNo open trial led
- 110 papers led
- 109 papers led
- 106 papers led
- 106 papers led
- 97 papers ledNo open trial led
- 96 papers led
- 95 papers led
- 91 papers led
- 88 papers led
- 83 papers led
- 83 papers led
- 81 papers led
- 80 papers led
- 79 papers led
- 77 papers led
- 77 papers led
- 77 papers led
- 76 papers led
- 76 papers led
- 75 papers led
- 74 papers led
- 74 papers led
- 72 papers ledNo open trial led
- 70 papers ledNo open trial led
- 70 papers ledNo open trial led
- 68 papers led
- 68 papers ledNo open trial led
- 67 papers ledNo open trial led
- 64 papers led
- 63 papers led
- 62 papers ledNo open trial led
- 60 papers ledNo open trial led
- 58 papers led
- 57 papers ledNo open trial led
- 56 papers led
- 55 papers ledNo open trial led
- 54 papers led
- 54 papers led
- 52 papers ledNo open trial led
- 51 papers ledNo open trial led
- 50 papers ledNo open trial led
- 50 papers led
- 50 papers ledNo open trial led
- 49 papers led
- 49 papers led
- 49 papers ledNo open trial led
- 49 papers led
- 48 papers ledNo open trial led
- 47 papers led
- 47 papers ledNo open trial led
- 47 papers led
- 45 papers led
- 45 papers led
- 45 papers ledNo open trial led
- 45 papers led
- 44 papers ledNo open trial led
- 44 papers led
- 44 papers led
- 44 papers ledNo open trial led
- 44 papers led
- 43 papers ledNo open trial led
- 43 papers ledNo open trial led
- 43 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 40 papers led
- 39 papers ledNo open trial led
- 39 papers ledNo open trial led
- 39 papers ledNo open trial led
- 38 papers led
- 38 papers ledNo open trial led
- 38 papers led
- 37 papers ledNo open trial led
- 36 papers ledNo open trial led
- 36 papers ledNo open trial led
- 36 papers ledNo open trial led
- 35 papers led
- 34 papers ledNo open trial led
- 31 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 29 papers led
- 29 papers led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers led
- 28 papers ledNo open trial led
- 28 papers ledNo open trial led
- 27 papers led
- 27 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers led
- 26 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 24 papers ledNo open trial led
- 24 papers ledNo open trial led
- 23 papers led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 22 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers led
- 17 papers ledNo open trial led
- 16 papers led
- 16 papers ledNo open trial led
- 16 papers led
- 16 papers ledNo open trial led
- 16 papers led
- 16 papers led
- 15 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers led
- 13 papers ledNo open trial led
- 12 papers led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 10 papers led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers led
- 6 papers ledNo open trial led
- 5 papers led
- 5 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
No listed hospital matches these filters.
By university or health system 60
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 589 papers led6 hospitals
- 585 papers led6 hospitals
- 529 papers led6 hospitals
- 440 papers led6 hospitals
- 398 papers led6 hospitals
- 373 papers led6 hospitals
- 323 papers led6 hospitals
- 312 papers led6 hospitals
- 297 papers led6 hospitals
- 293 papers led6 hospitals
- 285 papers led6 hospitals
- 274 papers led6 hospitals
- 266 papers led6 hospitals
- 263 papers led6 hospitals
- 260 papers led6 hospitals
- 258 papers led6 hospitals
- 252 papers led6 hospitals
- 240 papers led6 hospitals
- 207 papers led6 hospitals
- 190 papers led3 hospitals
- 188 papers led6 hospitals
- 186 papers led6 hospitals
- 181 papers led6 hospitals
- 178 papers led6 hospitals
- 168 papers led2 hospitals
- 160 papers led5 hospitals
- 144 papers led6 hospitals
- 143 papers led6 hospitals
- 136 papers led6 hospitals
- 131 papers led6 hospitals
- 122 papers led6 hospitals
- 119 papers led6 hospitals
- 118 papers led6 hospitals
- 116 papers led1 hospital
- 114 papers led6 hospitals
- 110 papers led1 hospital
- 107 papers led6 hospitals
- 100 papers led3 hospitals
- 97 papers led3 hospitals
- 91 papers led1 hospital
- 90 papers led6 hospitals
- 89 papers led6 hospitals
- 88 papers led3 hospitals
- 88 papers led1 hospital
- 87 papers led4 hospitals
- 85 papers led6 hospitals
- 83 papers led6 hospitals
- 79 papers led1 hospital
- 78 papers led2 hospitals
- 78 papers led6 hospitals
- 66 papers led6 hospitals
- 60 papers led6 hospitals
- 58 papers led6 hospitals
- 55 papers led3 hospitals
- 53 papers led4 hospitals
- 28 papers led5 hospitals
- 26 papers led1 hospital
- 24 papers led1 hospital
- 24 papers led1 hospital
- 2 papers led1 hospital
open trials on breast cancer in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 597 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingSacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT06462092
Age 18 years to 75 years (registered criteria)
Led by Affiliated Huizhou Hospital of Guangzhou Medical UniversityHuizhou
- RecruitingA Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT06889610
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingReal-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT06993506
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingHypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07084519
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingThe Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07203729
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07208149
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Changsha, Wuhan
- RecruitingPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07235176
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07238894
Age 18 years to 80 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07281976
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou
- RecruitingNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07283692
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07294508
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07321015
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingQL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07342283
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- RecruitingA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07347600
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07349069
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingA Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07352930
Age 18 years to Not stated; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07354022
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical Mastectomy
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07365267
Age 18 years to 70 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingCDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07366112
Age 18 years to 75 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingNeoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07372079
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingThe Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07376174
Age 18 years to Not stated; women only (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingResponse-Based Local Therapy for Regionally Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07376538
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingFMD and Neoadjuvant Chemo-immunotherapy in TNBC
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07378306
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Recruitingthe Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07380646
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07383818
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an
- RecruitingA Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07389733
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Dalian
- RecruitingNeoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07393425
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07396324
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingStudy on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07396454
Age 18 years to 70 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingRibociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07400523
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 2 listed hospitals as study sitesGuangzhou, Shantou, Zhanjiang
- RecruitingEfficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
- Phase
- Phase 2/Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07410169
Age 18 years to 75 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07413939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan
- RecruitingCDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07432178
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07441460
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07457359
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07459283
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuxi
- RecruitingYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07461454
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07471776
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAblation Compare With Surgery for Early Breast Cancer
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07484087
Age 50 years to Not stated; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingDual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07486089
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingElectroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07490938
Age 18 years to 75 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesTianjin, Wuhan, Xining
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07497386
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07498478
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan
- RecruitingConstruction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07500428
Age 18 years to 75 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07510802
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07518173
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingA Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07520760
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingUltra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07527689
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingArtificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07528716
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07533123
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07540533
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingDigital Mind-Body Therapy for Neoadjuvant Breast Cancer
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07541664
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMegestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07543536
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07544056
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07551050
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07552467
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Recruiting18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07557225
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingOpportunistic Breast Cancer Screening Using Non-Contrast Chest CT
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07557654
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07581795
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07581834
Age 18 years to Not stated; women only (registered criteria)
Led by Fujian Cancer Hospital; 1 listed hospital as study siteChengdu, Fuzhou
- RecruitingA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07591090
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingReal-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
- Phase
- Phase 4
- Started
- 2026-07
- Posted
- Registry
- NCT07600164
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingQUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07601178
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- RecruitingMetronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07602907
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07610720
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingFovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07616427
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Nanjing
- RecruitingPilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07616440
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEfficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07616453
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07622836
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingSac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07623577
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07638852
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTrastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07647016
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07647029
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTrastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07647263
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07648914
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07658183
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPrecision Navigation to Improve Community Cancer Screening Participation
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07676383
Age 45 years to 74 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07678957
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingOlaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
- Phase
- Phase 4
- Started
- 2026-05
- Posted
- Registry
- NCT07695259
Age 60 years to Not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingClinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07697443
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan
- RecruitingBreast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07698366
Age 65 years to 80 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingPre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07702708
Age 18 years to Not stated; women only (registered criteria)
Led by Fujian Cancer Hospital; 2 listed hospitals as study sitesFuzhou, Quanzhou
- RecruitingExergames-acceptance and Commitment Therapy(e-ACT) for Breast Cancer Depression and Anxiety: A Randomized Controlled Trial
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07721753
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteXinxiang
- RecruitingSMP-656 for HER2-Positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07726342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
- Phase
- Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07729956
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCulmerciclib in HR+/HER2+ Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07732491
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingGB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07738341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPaclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07739485
Age 18 years to 70 years; women only (registered criteria)
Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang
- RecruitingPaclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07739511
Age 18 years to 70 years; women only (registered criteria)
Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang
- RecruitingA Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07743944
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07753226
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07757230
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingAnalysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07763587
Age 18 years to 70 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 1 listed hospital as study siteTianjin
- RecruitingEstablishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07773818
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingNeoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07796880
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingNeoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07797218
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingRisk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07817056
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingPhase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07817082
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingResponse-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07829848
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting1-Week Versus 3-Week PBI
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07832279
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingCAIX-targeted PET/CT in Solid Tumors
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07833085
Age 18 years to Not stated (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingHypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07835139
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingArtificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07844941
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingClinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07848243
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07876557
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
- RecruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880600
Age 18 years to Not stated; women only (registered criteria)
Led by Fujian Cancer Hospital; 2 listed hospitals as study sitesFuzhou, Quanzhou
- RecruitingA Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07900516
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingThalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients
- Phase
- N/A
- Started
- 2026-11
- Posted
- Registry
- NCT07933653
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- RecruitingNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT05321316
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingDalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06637150
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingARX788 in HER2-positive Metastatic Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06663748
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06679036
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou
- RecruitingA Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06686459
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingReverse HER2-negative Immune Resistant Breast Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06731140
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06738966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Jinan
- RecruitingEffects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06741540
Age 18 years to 65 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06756932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- RecruitingPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06757634
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou
- RecruitingAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06767527
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06769425
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingElectroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06772935
Age 18 years to 75 years; women only (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingTo Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06784921
Age 18 years to 75 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingCapecitabine in Low Risk Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06787339
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06790693
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang
- RecruitingBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06793332
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPosaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06802757
Age 18 years to 70 years; women only (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Phase IIa Study to Evaluate NBQ72S
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06810804
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06811870
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingTo Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06817954
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06827236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an
- RecruitingHypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06830083
Age 18 years to 65 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06830889
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingA Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06832202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06839547
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingEvaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06839560
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06841354
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06846437
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06847555
Age 18 years to Not stated; women only (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingThe Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06851299
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06856200
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital, Fudan UniversityShanghai
- RecruitingSerplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06860529
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingNeoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06874933
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou
- RecruitingPhase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06889688
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingProbiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT06892093
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingBortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06900647
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06902051
Age 18 years to 70 years; women only (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingTopical Diclofenac for Prevention of Radiation-induced Dermatitis
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06905561
Age 18 years to 75 years (registered criteria)
Led by Hainan General Hospital / Hainan Medical University hospitalsHaikou
- RecruitingEvaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06908668
Age 18 years to 70 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingAl18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06909604
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingNeoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06914440
Age 18 years to 75 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingClinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06916338
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingClinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06916637
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06926868
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingSHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06927180
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingClinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06938360
Age 18 years to 70 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingDevelopment and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06938373
Age 18 years to 80 years (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06942234
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingElectroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT06952920
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06957886
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingNeoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06964906
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Real World Study of Sacituzumab Govitecan
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06966141
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06966700
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingQL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06967103
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT06970912
Age 18 years to 75 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06974929
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06977893
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou
- RecruitingSacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT06991790
Age 18 years to 75 years; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingCirculating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06992336
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06992882
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting3D-printed Biodegradable Breast Implants for Breast Restoration
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06993714
Age 18 years to 70 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06993844
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Shanghai
- RecruitingGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT06994507
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingThe Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06995118
Age 18 years to 70 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou
- RecruitingA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07002177
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07003074
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan
- RecruitingClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07008976
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou
- RecruitingA Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07010939
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan
- RecruitingA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07024173
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingEfficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07037199
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07037576
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingJS207 Combination Therapy in Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07045311
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingTrop-2 Targeted PET Probes in Advanced TNBC
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07046455
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07047365
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou
- RecruitingEfficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07057427
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07060807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07062965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an
- RecruitingModulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT07066280
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07071337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingSC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07080619
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAdaptive Chemotherapy for the Treatment of Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07088263
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07095023
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou
- RecruitingBioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07096869
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07100106
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Jinan, Nanning, Shanghai, Tianjin
- RecruitingTrastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07100600
Age 18 years to Not stated; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07111832
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingProspective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07113613
Age 30 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07114601
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingAn Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07117630
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingExploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07117864
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingSHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07125950
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07130383
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07134153
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07150208
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingT-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07152782
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT07154563
Age 18 years to 75 years; women only (registered criteria)
Led by Yunnan Cancer HospitalKunming
- RecruitingStudy of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07156253
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07162298
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07173751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesHefei, Jinan, Lanzhou, Linyi, Nanchang, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07174336
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan
- RecruitingA Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
- Phase
- Phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07178171
Age 18 years to 70 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingAdjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07180056
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingContinuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07180082
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingIparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07180160
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingTrastuzumab Deruxtecan in Advanced Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07180264
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingSKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07182721
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07207070
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07213791
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAn Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07222267
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen
- RecruitingA Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07244094
Age 18 years to 95 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteChangchun, Hangzhou
- RecruitingA Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07250204
Age 18 years to Not stated (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingA Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07250386
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07252986
Age not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07258108
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingVSV-02 Compassionate Use in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07260591
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xinxiang Medical UniversityXinxiang
- RecruitingDIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07263347
Age 18 years to 70 years; women only (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingEfficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07263425
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingSafety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07263451
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingGut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07264985
Age 18 years to 75 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingObservational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07264998
Age 18 years to 75 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingA Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07274852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingPhase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT07284836
Age 18 years to 70 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingDifferent Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07285382
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesDalian, Qingdao
- RecruitingA Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07304934
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07321145
Age 18 years to 80 years; women only (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07330544
Age 18 years to Not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Recruiting68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07331532
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingNeoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07340398
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
- Phase
- Early phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT07340424
Age 18 years to Not stated; women only (registered criteria)
Led by Cancer Hospital, Shandong First Medical UniversityJinan
- RecruitingObservation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT07350928
Age 20 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07351487
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Hefei, Shanghai
- RecruitingEfficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07358182
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingCorticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT07362914
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMulticenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07371208
Age 18 years to 65 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAcupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07377279
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingctDNA-guided Treatment Decision-making
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07394218
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNeoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07394387
Age 18 years to 70 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEfficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07401537
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingReal-world Studies of CDK4/6 Inhibitors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07407439
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingAI-Enhanced Imaging in Population Breast Cancer Screening
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07411443
Age 35 years to 69 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT07455188
Age 18 years to Not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingDalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07467330
Age 18 years to Not stated; women only (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingLevel I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07469267
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan
- RecruitingDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07492394
Age 18 years to 75 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingRobustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07498855
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07532434
Age 18 years to Not stated; women only (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingEndoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07548762
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingMolecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07574749
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
- Phase
- Phase 4
- Started
- 2025-08
- Posted
- Registry
- NCT07578064
Age 18 years to 80 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07586826
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingThe Value of Time-Dependent Diffusion MRI and Magnetic Resonance Elastography in the Precise Diagnosis and Efficacy Assessment of Breast Cancer
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07608081
Age 18 years to 80 years; women only (registered criteria)
Led by Yunnan Cancer HospitalKunming
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07612891
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07653893
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOptimal Application Timing of ADC Drugs for Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07657130
Age 18 years to 75 years; women only (registered criteria)
Led by Liaoning Cancer Hospital & InstituteShenyang
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07708194
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingEfficacy of Kinesio Taping Versus Compression Therapy on Breast Lymphedema Induced by Radiotherapy After Breast-Conserving Surgery
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07767305
Age 18 years to Not stated (registered criteria)
Led by Tangshan People's HospitalTangshan
- RecruitingDalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07810088
Age 18 years to 75 years; women only (registered criteria)
Led by Union HospitalWuhan
- RecruitingPucotenlimab and Anlotinib in Combination With Chemotherapy
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07896668
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingTargeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT04744506
Age 18 years to 85 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEfficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT05578053
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingOrganoid-based Functional Precision Therapy for Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06102824
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingAdebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06149130
Age 18 years to 75 years; women only (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingCombination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06176534
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06197581
Age 18 years to 70 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingElectroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
- Phase
- Phase 3
- Started
- 2024-01
- Posted
- Registry
- NCT06200168
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06210776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai
- RecruitingThe Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
- Phase
- Phase 3
- Started
- 2024-01
- Posted
- Registry
- NCT06214195
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingIntrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
- Phase
- Phase 4
- Started
- 2024-01
- Posted
- Registry
- NCT06230055
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06235931
Age 65 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingThe Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06254690
Age 18 years to 70 years; women only (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingRandomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06255392
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDarsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06276868
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingEarly Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06282796
Age 18 years to 80 years; women only (registered criteria)
Led by First Hospital of China Medical University; 2 listed hospitals as study sitesFuzhou, Shenyang
- RecruitingDalpiciclib in HR+/HER2- ABC
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06301438
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingDP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06313086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06313463
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingElectroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06314906
Age 18 years to 75 years (registered criteria)
Led by Lanzhou University Second HospitalLanzhou
- RecruitingMinimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06319157
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingSHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06340230
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingCadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06367088
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06371274
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of GC203 TIL in Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06375187
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06383767
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingUtidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06385990
Age 18 years to 70 years; women only (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingLM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06387628
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingclinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
- Phase
- Not given
- Started
- 2024-03
- Posted
- Registry
- NCT06392217
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06401005
Age 18 years to Not stated; women only (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingSBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06402435
Age 18 years to Not stated; women only (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingBoost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06404697
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingApplication of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
- Phase
- Early phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06411678
Age 18 years to 70 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingAdebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06418594
Age 18 years to Not stated; women only (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingThe Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery
- Phase
- Not given
- Started
- 2024-02
- Posted
- Registry
- NCT06425874
Age 18 years to 50 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06433609
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06439771
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06452706
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an
- RecruitingRandomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06464913
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06471205
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06492005
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06493864
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06495515
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingEliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06498154
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06500208
Age 18 years to 65 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06503783
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai
- RecruitingNeoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06516289
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAxillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06518135
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingAn In-situ Detection for MicroRNA
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06529614
Age 18 years to 75 years; women only (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06531486
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06533384
Age 18 years to 70 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06534762
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingTislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06538896
Age 18 years to 70 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingEfficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06543992
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingA Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06555068
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Recruiting68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06559371
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingInternal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06559696
Age 18 years to 75 years; women only (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingA Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06567353
Age 18 years to 75 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingHypofractionated Online Adaptive Radiotherapy of Breast Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06568705
Age 35 years to 70 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingRibociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06587789
Age 18 years to 80 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAssessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06596018
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06596915
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06598046
Age 18 years to Not stated; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingStudy on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06601621
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingElectroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06602167
Age 18 years to 85 years (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingA Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06609187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06611813
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou
- RecruitingSBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06627712
Age 18 years to 65 years; women only (registered criteria)
Led by West China HospitalChengdu
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingAll Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer:a Multi-center, Multi-cohort Phase II Trial
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06636981
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
- Phase
- Phase 4
- Started
- 2024-10
- Posted
- Registry
- NCT06641544
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPlatform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06649331
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingProspective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06649565
Age 18 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingDrug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06658080
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou
- RecruitingLarge Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06660628
Age 18 years to 70 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingStudy of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06666270
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingNeoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06671262
Age 18 years to 85 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06677879
Age 18 years to 80 years; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingArsenous Acid for Refractory Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06678048
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06682195
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou
- RecruitingThe Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06690645
Age 18 years to Not stated; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingNeoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06697938
Age 18 years to 70 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingThe Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06698679
Age 18 years to Not stated; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingRadiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06705127
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT06713161
Age 18 years to 75 years; women only (registered criteria)
Led by Yunnan Cancer HospitalKunming
- RecruitingEstablishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06715020
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingTarget-specific immunoPET Imaging of Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06715826
Age 18 years to 75 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingLong-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06716073
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingThe Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06718010
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingImpact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06725082
Age 18 years to 80 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingGzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06725940
Age 18 years to 65 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAnlotinib-based Combination Therapy in Patients with Hormone Receptor-positive(HR+) Metastatic Breast Cancer(MBC) .
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06734533
Age 18 years to 75 years; women only (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingThe Optimal Radioimmunotherapy Combinations for Advanced TNBC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06735131
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingHypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06757621
Age 45 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingThe Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06770296
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingPhase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06771609
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingEffect of Subanesthetic Dose of Esketamine on Sleep Quality
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06773143
Age 18 years to 65 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT06776861
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingNabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06781281
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingQL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06786026
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06817525
Age 18 years to 65 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingSafety and Efficacy of IMPT or IMRT for Breast Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06826885
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06832904
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06878625
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Recruiting21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06891651
Age 65 years to Not stated; women only (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingApplication of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06911528
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingObservational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06918262
Age not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06950086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
- Phase
- Phase 2/Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06958627
Age 18 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingResearch on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT07012720
Age 25 years to 75 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingA Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT07019233
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingEvaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT07037537
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingPET/CT for Trop2 ADC Response Evaluation Cancers
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT07046689
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingRC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT07065435
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingUltra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT07135661
Age 40 years to Not stated; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingEvaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT07251868
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingctDNA in HER2+ EBC Neoadjuvant Treatment
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT07335081
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingDisitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT07446452
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT07635342
Age 18 years to 65 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingMecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT07899099
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT07923214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai
- RecruitingProphylactic Irradiation to the Contralateral Breast for BCAs Patients
- Phase
- N/A
- Started
- 2023-01
- Posted
- Registry
- NCT04960839
Age 30 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 5 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingEfficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT05212454
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingImpact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
- Phase
- N/A
- Started
- 2023-05
- Posted
- Registry
- NCT05494502
Age 18 years to 85 years (registered criteria)
Led by Peking University First Hospital; 1 listed hospital as study siteBeijing
- RecruitingUTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
- Phase
- Phase 1/Phase 2
- Started
- 2023-01
- Posted
- Registry
- NCT05535413
Age 18 years to 70 years; women only (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05635487
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05646862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan
- RecruitingA Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
- Phase
- Phase 2
- Started
- 2023-01
- Posted
- Registry
- NCT05692674
Age 18 years to 80 years; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingPirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05704166
Age 18 years to 75 years; women only (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-04
- Posted
- Registry
- NCT05744687
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan
- RecruitingFUSCC Refractory TNBC Platform Study (FUTURE2.0)
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05749588
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05759546
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingFamitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT05760378
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT05760612
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05769010
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingCDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
- Phase
- Not given
- Started
- 2023-04
- Posted
- Registry
- NCT05795335
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPrecise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-04
- Posted
- Registry
- NCT05806060
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRC48-ADC in HER2-low Advanced Breast Cancer
- Phase
- N/A
- Started
- 2023-05
- Posted
- Registry
- NCT05831878
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPyrotinib in Women With High-risk in Early Stage Breast Cancer
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05834764
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingIntegrin αvβ6-targeted PET in Malignant Tumors
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT05835570
Age 18 years to 85 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingDisitamab Vedotin (RC48-ADC) in Breast Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT05851677
Age not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05860465
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan
- RecruitingAdjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05861271
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05862064
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05872347
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou
- RecruitingCapecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
- Phase
- N/A
- Started
- 2023-06
- Posted
- Registry
- NCT05876065
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingEC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05883852
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05891093
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT05891561
Age 18 years to 75 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05894239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan
- RecruitingTCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05901428
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingDisitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
- Phase
- Phase 3
- Started
- 2023-07
- Posted
- Registry
- NCT05904964
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou, Shantou
- RecruitingStudy of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05909332
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingContinuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05910398
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05911958
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingComparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05918328
Age 18 years to 65 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingOmission of SLNB in CN0 Early Breast Cancer
- Phase
- N/A
- Started
- 2023-06
- Posted
- Registry
- NCT05935150
Age 18 years to 70 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingOmission of ALND in Breast Cancer Patients With Axillary pCR
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT05939830
Age 18 years to 70 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEfficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05949541
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT05950945
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou
- RecruitingRegional Lymph Node Irradiation for High-risk pN0 Breast Cancer
- Phase
- N/A
- Started
- 2023-07
- Posted
- Registry
- NCT05976412
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingStudy of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05981001
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05981014
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingChidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05983107
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
- Phase
- Phase 3
- Started
- 2023-08
- Posted
- Registry
- NCT05999149
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of Neoadjuvant TCHpy(Pyrotinib ,Trastuzumab,Carboplatin and Paclitaxel)for ER+/HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT06000917
Age 18 years to 75 years; women only (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06001086
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingReal-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT06033287
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingPyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT06035016
Age 18 years to 75 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
- Phase
- N/A
- Started
- 2023-08
- Posted
- Registry
- NCT06035679
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital of Fujan Medical University
- RecruitingA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06042894
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Posted
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06081959
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Recruiting99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06104085
Age 18 years to 80 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingDalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06107673
Age 18 years to 75 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
- RecruitingBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06120283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang
- RecruitingPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06121557
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06121570
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingOrganoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06155305
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06165900
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingClinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06167694
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06178159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT06227117
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin
- RecruitingDisitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT06278870
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingAI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
- Phase
- Not given
- Started
- 2023-03
- Posted
- Registry
- NCT06286267
Age not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEfficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06341894
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingExploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT06413212
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Recruitinga Single-arm, Single-center, Open Clinical Study
- Phase
- Not given
- Started
- 2023-07
- Posted
- Registry
- NCT06431100
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT06508307
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingTo Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
- Phase
- Not given
- Started
- 2023-04
- Posted
- Registry
- NCT06605521
Age 18 years to 80 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingPhotoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
- Phase
- N/A
- Started
- 2023-06
- Posted
- Registry
- NCT06908291
Age 18 years to Not stated; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT07014410
Age 18 years to 75 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT07073755
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingThe Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
- Phase
- N/A
- Started
- 2023-03
- Posted
- Registry
- NCT07638774
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingComparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
- Phase
- N/A
- Started
- 2023-07
- Posted
- Registry
- NCT07920094
Age 18 years to 70 years; women only (registered criteria)
Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou
- RecruitingReverse Triple Negative Immune Resistant Breast Cancer
- Phase
- Phase 2
- Started
- 2022-06
- Posted
- Registry
- NCT05076682
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAlbumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
- Phase
- Phase 2
- Started
- 2022-01
- Posted
- Registry
- NCT05192798
Age 18 years to 80 years; women only (registered criteria)
Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingPyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
- Phase
- Phase 2
- Started
- 2022-02
- Posted
- Registry
- NCT05228951
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingThe Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05263570
Age 18 years to Not stated; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingAnlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2022-03
- Posted
- Registry
- NCT05296577
Age 18 years to Not stated; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingAssessment of Brain Cognitive Impairment in Breast Cancer
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05305092
Age not stated; women only (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingEffectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05341141
Age 20 years to 70 years; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
- Phase
- Early phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT05341492
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAdopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
- Phase
- N/A
- Started
- 2022-03
- Posted
- Registry
- NCT05345860
Age 18 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingProne Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer
- Phase
- N/A
- Started
- 2022-03
- Posted
- Registry
- NCT05346510
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingCTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
- Phase
- N/A
- Started
- 2022-09
- Posted
- Registry
- NCT05360290
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05398861
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study for the Neoadjuvant Treatment of Breast Cancer
- Phase
- Phase 4
- Started
- 2022-07
- Posted
- Registry
- NCT05420454
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study for the Adjuvant Treatment of Breast Cancer
- Phase
- Phase 4
- Started
- 2022-07
- Posted
- Registry
- NCT05420467
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingUtidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2022-06
- Posted
- Registry
- NCT05430399
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingStudy of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05447702
Age 18 years to 75 years; women only (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05461768
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Wuhan, Zhengzhou
- RecruitingA Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05470348
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingClinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05475678
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05490472
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan
- RecruitingPatient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
- Phase
- N/A
- Started
- 2022-08
- Posted
- Registry
- NCT05512286
Age 18 years to Not stated; women only (registered criteria)
Led by Huashan Hospital; 2 listed hospitals as study sitesChangsha, Shanghai, Zhengzhou
- RecruitingChemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2022-03
- Posted
- Registry
- NCT05525767
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Recruiting68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
- Phase
- Early phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05549024
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingGQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05575804
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingFluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study
- Phase
- Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05576389
Age 18 years to Not stated; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05582499
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05594095
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05603078
Age Not stated to 55 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingPre-operative Therapy in Breast Cancer
- Phase
- Not given
- Started
- 2022-11
- Posted
- Registry
- NCT05621564
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05638594
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingObservational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05731258
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05761470
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingUltra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05762900
Age 35 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingOptical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2022-04
- Posted
- Registry
- NCT05804916
Age 18 years to 70 years; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingComparison Between Prepectoral and Subpectoral Breast Reconstruction
- Phase
- Not given
- Started
- 2022-03
- Posted
- Registry
- NCT05833659
Age 18 years to 70 years; women only (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05851014
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou
- RecruitingEfficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
- Phase
- Not given
- Started
- 2022-03
- Posted
- Registry
- NCT05856383
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingCold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
- Phase
- N/A
- Started
- 2022-11
- Posted
- Registry
- NCT06024187
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT06313983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT06551220
Age 18 years to 80 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai
- RecruitingSuper-Hypofractionated Partial Breast Irradiation
- Phase
- N/A
- Started
- 2022-04
- Posted
- Registry
- NCT06615466
Age 45 years to 74 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2022-09
- Posted
- Registry
- NCT06954961
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- RecruitingStudy of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
- Phase
- Phase 3
- Started
- 2022-06
- Posted
- Registry
- NCT06998108
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRegional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
- Phase
- Not given
- Started
- 2022-07
- Posted
- Registry
- NCT07179744
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingAlbumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-07
- Posted
- Registry
- NCT04136782
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang
- RecruitingTreatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
- Phase
- Phase 3
- Started
- 2021-07
- Posted
- Registry
- NCT04137653
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingSj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
- Phase
- Not given
- Started
- 2021-07
- Posted
- Registry
- NCT04476485
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang
- RecruitingEvaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
- Phase
- N/A
- Started
- 2021-03
- Posted
- Registry
- NCT04517266
Age 18 years to 80 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingStandard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2021-04
- Posted
- Registry
- NCT04722978
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2021-03
- Posted
- Registry
- NCT04750122
Age 18 years to 75 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
- RecruitingA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
- Phase
- Phase 2/Phase 3
- Started
- 2021-04
- Posted
- Registry
- NCT04803539
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingNeoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04836156
Age 18 years to 75 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-01
- Posted
- Registry
- NCT04842812
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSingle Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2021-01
- Posted
- Registry
- NCT04947280
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT04983121
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingThe Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT05032768
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMedial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
- Phase
- Phase 3
- Started
- 2021-09
- Posted
- Registry
- NCT05059379
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
- Phase
- Phase 3
- Started
- 2021-09
- Posted
- Registry
- NCT05063136
Age 18 years to 70 years; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of GC101 TIL in Advanced Breast Cancer (10hospital)
- Phase
- Early phase 1
- Started
- 2021-11
- Posted
- Registry
- NCT05142475
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2021-12
- Posted
- Registry
- NCT05159193
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAxillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy
- Phase
- N/A
- Started
- 2021-11
- Posted
- Registry
- NCT05241119
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang
- RecruitingCompare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2021-07
- Posted
- Registry
- NCT05292742
Age 18 years to 75 years; women only (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingNeoadjuvant Radiation in Locally Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2021-03
- Posted
- Registry
- NCT05479409
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEstrogen Receptor (ER) PET/CT Imaging in Breast Cancer
- Phase
- Not given
- Started
- 2021-12
- Posted
- Registry
- NCT05541367
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNeoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT05728268
Age 18 years to 70 years; women only (registered criteria)
Led by Shantou Central HospitalShantou
- RecruitingA Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
- Phase
- N/A
- Started
- 2021-11
- Posted
- Registry
- NCT06234137
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingPyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
- Phase
- Not given
- Started
- 2021-06
- Posted
- Registry
- NCT06754059
Age 18 years to 70 years; women only (registered criteria)
Led by Fujian Union Medical College HospitalFuzhou
- RecruitingApplication of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer
- Phase
- N/A
- Started
- 2021-08
- Posted
- Registry
- NCT07776301
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRadical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
- Phase
- N/A
- Started
- 2020-05
- Posted
- Registry
- NCT04158843
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingMarkers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
- Phase
- N/A
- Started
- 2020-04
- Posted
- Registry
- NCT04281641
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTrastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2020-07
- Posted
- Registry
- NCT04481932
Age 18 years to 70 years; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
- Phase
- Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04501523
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04557449
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2020-09
- Posted
- Registry
- NCT04576143
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2020-11
- Posted
- Registry
- NCT04606446
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an
- RecruitingFulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2020-10
- Posted
- Registry
- NCT04646759
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingNomogram to Predict Breast Cancer Related Lymphedema
- Phase
- N/A
- Started
- 2020-12
- Posted
- Registry
- NCT04665882
Age 18 years to 80 years; women only (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingSelective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT
- Phase
- N/A
- Started
- 2020-07
- Posted
- Registry
- NCT05314114
Age 18 years to 70 years; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingClinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
- Phase
- Not given
- Started
- 2020-11
- Posted
- Registry
- NCT06375798
Age 55 years to Not stated; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingHypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment
- Phase
- Phase 3
- Started
- 2019-02
- Posted
- Registry
- NCT03829553
Age 18 years to 75 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCirculating Tumor Cell Detection in Patients With Luminal A Breast Cancer
- Phase
- Not given
- Started
- 2019-10
- Posted
- Registry
- NCT04065321
Age 18 years to 60 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang
- RecruitingRecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
- Phase
- N/A
- Started
- 2019-08
- Posted
- Registry
- NCT04069884
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingSentinel Node Biopsy Vs Observation After Axillary PET
- Phase
- N/A
- Started
- 2019-09
- Posted
- Registry
- NCT04072653
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
- Phase
- Phase 2
- Started
- 2019-11
- Posted
- Registry
- NCT04138719
Age 18 years to 70 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingNab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2019-11
- Posted
- Registry
- NCT04159142
Age 18 years to 70 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingAdjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2019-12
- Posted
- Registry
- NCT04254263
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingEvaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
- Phase
- Not given
- Started
- 2019-03
- Posted
- Registry
- NCT05326295
Age 18 years to 75 years; women only (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingDe-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06692725
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingAdjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06693024
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingAdjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06693037
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingDifferent Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06700382
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingAdjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06711068
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingFour Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06722599
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingChemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06722612
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Posted
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingHypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
- Phase
- N/A
- Started
- 2018-07
- Posted
- Registry
- NCT04025164
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesDalian, Guiyang, Shanghai
- RecruitingFulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2018-05
- Posted
- Registry
- NCT04263298
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Shenzhen, Zhanjiang
- RecruitingApplication of Radiomics in Breast Cancer
- Phase
- Not given
- Started
- 2018-01
- Posted
- Registry
- NCT04483804
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEvaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer
- Phase
- Not given
- Started
- 2017-06
- Posted
- Registry
- NCT03177902
Age 18 years to 85 years; women only (registered criteria)
Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu
- RecruitingAddition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
- Phase
- Phase 3
- Started
- 2017-07
- Posted
- Registry
- NCT03201861
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingStereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
- Phase
- Phase 2
- Started
- 2017-08
- Posted
- Registry
- NCT03392233
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingNeoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2015-07
- Posted
- Registry
- NCT02535221
Age 35 years to 55 years; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingDe-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
- Phase
- Not given
- Started
- 2015-01
- Posted
- Registry
- NCT06700369
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTaxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
- Phase
- Not given
- Started
- 2015-01
- Posted
- Registry
- NCT06711055
Age not stated; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
- Phase
- Phase 1
- Started
- 2013-01
- Posted
- Registry
- NCT02897700
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- Not yet recruitingRe-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2027-01
- Posted
- Registry
- NCT07419880
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingADC Based Therapy Accroding to HER2 Heterogeneous
- Phase
- Phase 2
- Started
- 2027-01
- Posted
- Registry
- NCT07844018
Age 18 years to Not stated; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingA Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07235618
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingBone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07255612
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07294339
Age 18 years to 75 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingCellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07311317
Age 18 years to 70 years; women only (registered criteria)
Led by West China Hospital; 1 listed hospital as study siteChengdu
- Not yet recruitingChemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07317778
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingJSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07336771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingHuaier Granule and Proteinuria
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07355361
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingEffect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07367542
Age 18 years to Not stated; women only (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingEfficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07380230
Age 18 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingFamitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07382687
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingNeoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07410559
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingPedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07415200
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingA Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07419867
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07423611
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingEffect of Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Breast Cancer Surgery Patients
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07458646
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingSerplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07466303
Age 18 years to 70 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingStudy of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07466927
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingEffect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07481903
Age 18 years to 75 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin
- Not yet recruitingPhase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07487519
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin
- Not yet recruitingDecision Aid for Women Newly Diagnosed With Breast Cancer
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07497256
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesXiamen
- Not yet recruitingBaduanjin Exercise on Upper Limb Dysfunction Among Breast Cancer Survivors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07522593
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZunyi
- Not yet recruitingComparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07523789
Age 18 years to Not stated; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingNeoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07528898
Age 18 years to 70 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingEffects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07533526
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingProton vs Photon IMRT Toxicity in Breast Cancer
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07537712
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingThe Comparison Between M-E-BCS and C-O-BCS.
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07539545
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07539753
Age 18 years to 75 years; women only (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingAreola Preservation in NSM With Nipple Involvement
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07544134
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07556848
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07560124
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Harbin
- Not yet recruitingExploratory Study of SHR-A1811 Via Different Administration Routes in Patients
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07560475
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruiting5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07589101
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingClinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced Pain
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07593365
Age 18 years to Not stated; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingThe Comparison Between DEDTI BR and T/E BR
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07593846
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingUltrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07596472
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingSuper-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07623226
Age 18 years to 75 years; women only (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingSac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07628504
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingEfficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07630103
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingMolecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07657169
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 3 listed hospitals as study sitesGuangzhou, Jinan, Qingdao, Shenzhen
- Not yet recruitingRisk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07657442
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07672743
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEfficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07684456
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingResearch on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07689929
Age not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingKumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07691333
Age 18 years to 75 years; women only (registered criteria)
Led by Fujian Cancer Hospital; 2 listed hospitals as study sitesFuzhou, Quanzhou
- Not yet recruitingCulmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07745257
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou
- Not yet recruitingRetlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07752550
Age 18 years to 100 years; women only (registered criteria)
Led by Harbin Medical University Cancer HospitalHarbin
- Not yet recruitingA Comparative Study of Delayed Endoscopic DTI and Latissimus Dorsi ±Impalnt Reconstruction Post-Mastectomy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07757074
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingTrastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07766772
Age 18 years to 75 years; women only (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Not yet recruitingResearch on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07767565
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingRomiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07771881
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07782086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou
- Not yet recruitingSHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07787338
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingSLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary Nodes
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07791771
Age 18 years to Not stated; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingCulmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07795424
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang
- Not yet recruitingNeoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07801898
Age 18 years to 18 years (registered criteria)
Led by Second Affiliated Hospital of Anhui Medical UniversityHefei
- Not yet recruitingProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07825753
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07836257
Age 18 years to Not stated (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Not yet recruitingChinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07848984
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingImpact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07850154
Age not stated (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- Not yet recruitingSHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07856303
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080
- Phase
- Phase 1
- Started
- 2026-11
- Posted
- Registry
- NCT07876596
Age 18 years to 55 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingExploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07888556
Age not stated; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingTrastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07892274
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingAdding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07892508
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07894328
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingAlbumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07899047
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingStudy on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07942103
Age 18 years to 70 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- Not yet recruitingMultimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning
- Phase
- Not given
- Started
- 2026-11
- Posted
- Registry
- NCT07943494
Age not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingRandomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules
- Phase
- Phase 4
- Started
- 2025-09
- Posted
- Registry
- NCT05871437
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingExploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT06556862
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingHeterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06797622
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06798506
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingThis Study Aims to Explore the Efficacy of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06811857
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingHyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06819501
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06825949
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06825975
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingFamilial Breast Cancer in China
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06833216
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEstablishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06902935
Age 30 years to 75 years; women only (registered criteria)
Led by Taizhou HospitalTaizhou
- Not yet recruitingThe Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT06934733
Age 18 years to Not stated; women only (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingPatient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06965556
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingClinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT06994078
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingAcupuncture for Anxiety and Depression
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT06994351
Age 18 years to 70 years; women only (registered criteria)
Led by Guang'anmen HospitalBeijing
- Not yet recruitingChemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06996093
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingClinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07005583
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingEpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07018505
Age 18 years to 75 years; women only (registered criteria)
Led by Yunnan Cancer HospitalKunming
- Not yet recruitingA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07036185
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07040644
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingSHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07047443
Age 18 years to 75 years; women only (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- Not yet recruitingA Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07054242
Age 18 years to 75 years (registered criteria)
Led by Yantai Yuhuangding HospitalYantai
- Not yet recruitingHuman-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07060599
Age not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingComparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07061717
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingArtificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07063667
Age 19 years to 85 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingFasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07077018
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingStudy of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07088588
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingEfficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
- Phase
- Phase 4
- Started
- 2025-08
- Posted
- Registry
- NCT07093931
Age 18 years to 70 years; women only (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Not yet recruitingQL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07113964
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingEfficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07136974
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingSacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07139470
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingDe-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07153757
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07153965
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingCohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
- Phase
- Phase 4
- Started
- 2025-10
- Posted
- Registry
- NCT07162259
Age 18 years to 85 years; women only (registered criteria)
Led by Xi'an International Medical Center HospitalXi'an
- Not yet recruitingA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07163481
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingSimple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07169864
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingAcupuncture for Anxiety/Depression in Patients With Breast Cancer
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07183813
Age 18 years to 70 years; women only (registered criteria)
Led by Guang'anmen HospitalBeijing
- Not yet recruitingCorrelation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07188116
Age 18 years to 80 years; women only (registered criteria)
Led by Zhejiang Hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingDrain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07237828
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingEvaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07246317
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 4 listed hospitals as study sitesGuangzhou, Luoyang, Shijiazhuang, Tianjin
- Not yet recruitingCombined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07254858
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingA Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple Mastectomy
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07257003
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingRaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07269691
Age 18 years to 70 years; women only (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Not yet recruitingStudy of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06202313
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- Not yet recruitingAerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06234150
Age 18 years to 65 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingTrastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
- Phase
- Phase 4
- Started
- 2024-01
- Posted
- Registry
- NCT06245824
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingMyeloprotection With Trilaciclib in Pan-cancer Population
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06297811
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06354114
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin
- Not yet recruitingAromatherapy in the Treatment of Early Breast Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06435104
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingClinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging
- Phase
- N/A
- Started
- 2024-07
- Posted
- Registry
- NCT06475066
Age 18 years to 75 years; women only (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingNeoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06510465
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingT-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06548178
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingTo Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06561646
Age 18 years to 75 years; women only (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06614751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- Not yet recruitingComparing the Safety and Cosmetic Outcomes Between Laparoscopic Versus Traditional Open Breast-conserving Surgery
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06671249
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06724263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingJAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06731153
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingChidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06750848
Age 18 years to 75 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- Not yet recruitingA Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-12
- Posted
- Registry
- NCT06769919
Age 18 years to 65 years; women only (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingEfficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- Phase
- Phase 4
- Started
- 2023-07
- Posted
- Registry
- NCT05841849
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingClinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- Phase
- Phase 4
- Started
- 2023-10
- Posted
- Registry
- NCT05860907
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou
- Not yet recruitingStudy of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT05979220
Age 18 years to 75 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingStudy of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05983094
Age 18 years to 70 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEfficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06015113
Age 18 years to Not stated; women only (registered criteria)
Led by Xi'an International Medical Center HospitalXi'an
- Not yet recruitingThe Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06140576
Age 18 years to 70 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingThe Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
- Phase
- Phase 2
- Started
- 2022-06
- Posted
- Registry
- NCT05431504
Age 18 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingAcupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
- Phase
- N/A
- Started
- 2022-08
- Posted
- Registry
- NCT05460819
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- Not yet recruitingStudy on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer
- Phase
- Early phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05505812
Age 18 years to 75 years; women only (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingStudy of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
- Phase
- N/A
- Started
- 2022-12
- Posted
- Registry
- NCT05613504
Age 30 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- Not yet recruitingInetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- Phase
- Phase 3
- Started
- 2021-02
- Posted
- Registry
- NCT04736589
Age 18 years to 85 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingTrastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04973319
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- Not yet recruitingA Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients
- Phase
- Not given
- Started
- 2020-06
- Posted
- Registry
- NCT04426136
Age 70 years to Not stated; women only (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Enrolling by invitationEndoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07352137
Age 18 years to 70 years; women only (registered criteria)
Led by Guangdong Provincial Hospital of Chinese MedicineGuangzhou
- Enrolling by invitationFertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07376681
Age 18 years to 40 years; women only (registered criteria)
Led by Taizhou HospitalTaizhou
- Enrolling by invitationInfluencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast Cancer
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07419971
Age 18 years to 80 years; women only (registered criteria)
Led by West China HospitalChengdu
- Enrolling by invitationExercise Intervention for Breast Cancer Patients With Sarcopenia
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07732101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Enrolling by invitationMultigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06650748
Age 18 years to 70 years; women only (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Enrolling by invitationA Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06791161
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationA Study Comparing the Differences Between Young and Non-young Breast Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06793306
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationTrastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06843681
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Enrolling by invitationPaclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)
- Phase
- Phase 2/Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06910072
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationEfficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT06914661
Age 18 years to 100 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Enrolling by invitationBreast Cancer PET/CT Imaging With 68Ga-pAKTi
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06943313
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Enrolling by invitationPET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
- Phase
- Early phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07023848
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangnan UniversityWuxi
- Enrolling by invitationThe Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
- Phase
- Early phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07023861
Age 15 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangnan UniversityWuxi
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
- Enrolling by invitationImpact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07409298
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationConcept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07514728
Age 18 years to 75 years; women only (registered criteria)
Led by Central Hospital Affiliated to Shandong First Medical UniversityJinan
- Enrolling by invitationImmediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07798466
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Enrolling by invitationEffect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06405269
Age 18 years to 40 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationIntensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06405295
Age 18 years to 75 years; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationReal-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06881550
Age 18 years to 75 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- Enrolling by invitationRadiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06890871
Age 18 years to 75 years; women only (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Enrolling by invitationSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT07359404
Age 18 years to Not stated; women only (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitation18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT07859046
Age 18 years to 80 years; women only (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Enrolling by invitationInvestigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery
- Phase
- Not given
- Started
- 2023-07
- Posted
- Registry
- NCT06258863
Age 18 years to Not stated; women only (registered criteria)
Led by Hubei Cancer HospitalWuhan
- Enrolling by invitationT-DM1 Combined With CDK4/6 Inhibitor Ribociclib
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06481956
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Additional research sources
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.